Cargando…
Antimetabolite Treatment for Pancreatic Cancer
Pancreatic cancer is a deadly and aggressive disease. Less than 1% of diagnosed patients survive 5 years with an average survival time of only 4–8 months. The only option for metastatic pancreatic cancer is chemotherapy where only the antimetabolites gemcitabine and 5-fluorouracil are used clinicall...
Autores principales: | Valenzuela, Malyn May Asuncion, Neidigh, Jonathan W., Wall, Nathan R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494102/ https://www.ncbi.nlm.nih.gov/pubmed/26161298 http://dx.doi.org/10.4172/2167-7700.1000137 |
Ejemplares similares
-
Cell death in response to antimetabolites directed at ribonucleotide reductase and thymidylate synthase
por: Asuncion Valenzuela, Malyn M, et al.
Publicado: (2015) -
Problems in the Designing of Antimetabolites
por: Mautner, Henry G.
Publicado: (1960) -
A Study of Antimetabolites
Publicado: (1952) -
New antimetabolites in cancer chemotherapy and their clinical impact.
por: Kaye, S. B.
Publicado: (1998) -
Localization and upregulation of survivin in cancer health disparities: a clinical perspective
por: Khan, Salma, et al.
Publicado: (2015)